TeamViewer Shares Fall Despite Profit Growth as ARR and Customer Base Decline 
Meta CEO Zuckerberg Opposes U.S. Ban on Chinese AI Models, Warns Against Overregulation 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Philips Shares Slide 10% Despite Earnings Beat as Weak Orders Raise Growth Concerns 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Sika Raises 2026 Sales Outlook After Strong First-Half Results Beat Expectations 
Unilever Raises 2026 Sales Outlook After Strong Q2 Volume Growth 
Air Liquide Q2 Sales Growth Tops Forecast as Electronics Business Drives Strong Performance 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Exosens H1 Profit Beats Forecasts as Defense Demand Drives Growth 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
SAN DIEGO, Nov. 08, 2017 -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced that the company will participate in the Stifel 2017 Healthcare Conference in New York, NY.
The Company will be presenting at 9:30 AM Eastern on Wednesday, November 15, 2017. A live webcast of the presentation will be available on the Investor Relations page of the Company's website at: http://ir.vitaltherapies.com/. An archive of the presentation will be available for replay following the conference.
About Vital Therapies, Inc.
Vital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting the treatment of acute forms of liver failure. The Company’s ELAD System is an extracorporeal human allogeneic cellular liver therapy currently in phase 3 clinical trials. Vital Therapies, Inc. is based in San Diego, California. Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.
Contact:
Vital Therapies, Inc.
Al Kildani
Vice President, Investor Relations and Business Development
858-673-6840
[email protected]
